Literature DB >> 6966117

Lymphocyte subpopulations in patients with various immunodeficiencies.

F Gmelig-Meyling, I Dollekamp, B J Zegers, R E Ballieux, J W Stoop.   

Abstract

We have studied patients with various immunodeficiencies for the occurrence of blood lymphocytes bearing six different surface markers: the affinity to sheep erythrocytes (Es) to identify T cells, the presence of surface-bound immunoglobulins (sIg) to distinguish B cells, the affinity to mouse erythrocytes (Em) as a second B cell marker, and the receptors for the Fc part of IgM (IgM-FcR), the Fc part of IgG (IgG-FcR) and for complement (CR). IgG-FcR bearing lymphocytes were present in normal proportions and the same was found for CR-positive lymphocytes. None of the patients with congenital agammaglobulinaemia had sIg-bearing or Em-binding B lymphocytes. Four patients with ataxia teleangiectasia had low B cells and 3 out of 4 also had low proportions of IgM-FcR-bearing (T) cells. A child with partial DiGeorge syndrome did not have a grossly abnormal marker pattern although there appeared to be a shift in the T/B cell ratio in favour of the B cells. In a patient with selective cellular immunodeficiency associated with a purine nucleoside phosphorylase deficiency, who was followed during reconstitution therapy with plasma and red cells, a positive change in the marker pattern was seen. Similar observations were made in a child with combined immunodeficiency during treatment. The findings are being discussed in the light of the current knowledge of the functions and ontogeny of lymphocyte subsets.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6966117     DOI: 10.1111/j.1651-2227.1980.tb07059.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  1 in total

1.  Antibody responses in vivo in chromosome instability syndromes with immunodeficiency.

Authors:  C M Weemaes; T H The; P J van Munster; J A Bakkeren
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.